再程放疗临床实践:ESTRO-EORTC E2-RADIatE平台框架下的国际实践模式调查结果
2022年3月至9月开展的国际横断面调查,覆盖55个国家371名肿瘤放疗医生,旨在了解再程放疗的实践模式。结果显示脑部是最常见再程放疗部位(77%),延长局部控制为主要目标(各解剖区域90-96%),持续≥3级放射性毒性为最主要禁忌证(77-80%),机构指南匮乏(16-19%),需前瞻性研究提供高质量证据。
要点
- 脑部为最常见再程放疗部位(77%),其次为盆腔(65%)和头颈部(63%)。
- 持续≥3级放射性毒性是首要禁忌证(77-80%),最常见最小间隔为6-12个月(45-55%)。
- 仅16-19%的参与者报告所在机构有再程放疗指南,危及器官剂量约束存在差异。
核心结论
- 研究凸显再程放疗实践在不同解剖区域间存在异质性,并强调需要前瞻性研究的高质量证据来指导治疗决策和推导安全的累积剂量约束。
研究设计与样本
- 2022年3月至9月开展的国际横断面调查,由欧洲放射肿瘤学会(ESTRO)和欧洲癌症研究与治疗组织(EORTC)背书,调查对象为放疗和临床肿瘤医生,共371名来自55个国家的医生参与,中位专业经验16年,60%隶属于学术医院。
主要发现
- 脑部是最常见再程放疗部位(77%),其次为盆腔(65%)和头颈部(63%)。
- 延长局部控制是最常见目标(各解剖区域90-96%)。
- 最常见的最小再程放疗间隔为6-12个月(45-55%)。
- 持续≥3级放射性毒性是首要禁忌证(77-80%)。
- 观察到再程放疗的危及器官剂量约束存在变异性,先进影像模式和适形放疗技术被主要使用,机构指南匮乏(16-19%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Re-irradiation is an increasingly utilized treatment for recurrent, metastatic or new malignancies after previous radiotherapy. It is unclear how re-irradiation is applied in clinical practice. We aimed to investigate the patterns of care of re-irradiation internationally. MATERIAL/METHODS: A cross-sectional survey conducted between March and September 2022. The survey was structured into six sections, each corresponding to a specific anatomical region. Participants were instructed to complete the sections of their clinical expertise. A total of 15 multiple-choice questions were included in each section, addressing various aspects of the re-irradiation process. The online survey targeted radiation and clinical oncologists and was endorsed by the European Society for Radiotherapy and Oncology (ESTRO) and the European Organisation for Research and Treatment of Cancer (EORTC). RESULTS: 371 physicians from 55 countries across six continents participated. Participants had a median professional experience of 16 years, and the majority (60%) were affiliated with an academic hospital. The brain region was the most common site for re-irradiation (77%), followed by the pelvis (65%) and head and neck (63%). Prolonging local control was the most common goal (90-96% across anatomical regions). The most common minimum interval between previous radiotherapy and re-irradiation was 6-12 months (45-55%). Persistent grade 3 or greater radiation-induced toxicity (77-80%) was the leading contraindication. Variability in organs at risk dose constraints for re-irradiation was observed. Advanced imaging modalities and conformal radiotherapy techniques were predominantly used. A scarcity of institutional guidelines for re-irradiation was reported (16-19%). Participants from European centers more frequently applied thoracic and abdominal re-irradiation. Indications did not differ between academic and non-academic hospitals. CONCLUSION: This study highlights the heterogeneity in re-irradiation practices across anatomical regions and emphasizes the need for high-quality evidence from prospective studies to guide treatment decisions and derive safe cumulative dose constraints.
引用
- Willmann J, Appelt AL, Balermpas P, et al. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiother Oncol. 2023. PMID: 37806559. doi:10.1016/j.radonc.2023.109947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。